Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamou

2. Lilly does not recommend any off-label usage. SOURCE Innovent Biologics, Inc.
